Trials / Terminated
TerminatedNCT03057743
Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pilot study using \[18F\]ISO-1 PET/CT to image sigma-2 receptor binding in metastatic breast cancer. Correlate baseline uptake and change in uptake after therapy with time to progression and standard and experimental pathology assays of biopsy or surgical tissue. The target population is up to 30 adult patients at least 18 years, with at least one site of disease outside the liver by at least one type of standard imaging.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Positron emission tomography (PET/CT) imaging | |
| DEVICE | radiotracer [18F]ISO-1 |
Timeline
- Start date
- 2016-04-05
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
- First posted
- 2017-02-20
- Last updated
- 2021-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03057743. Inclusion in this directory is not an endorsement.